Copyright
©The Author(s) 2022.
World J Diabetes. Feb 15, 2022; 13(2): 85-96
Published online Feb 15, 2022. doi: 10.4239/wjd.v13.i2.85
Published online Feb 15, 2022. doi: 10.4239/wjd.v13.i2.85
Table 2 Renal dosing of dipeptidyl peptidase 4 inhibitors
| Renal impairment | Alogliptin | Linagliptin | Sitagliptin | Vildagliptin | Saxagliptin |
| Mild (eGFR > 50 mL/min) | 25 mg o.d. | 5 mg o.d. | 100 mg o.d. | 50 mg b.i.d. | 5 mg o.d. |
| Moderate (eGFR 30-50 mL/min) | 12.5 mg o.d. | 5mg o.d. | 50 mg o.d. | 50 mg o.d. | 2.5 mg o.d. |
| Severe (eGFR < 30 mL/min) | 6.25 mg o.d. | 5 mg o.d. | 25 mg o.d. | 50 mg o.d. | 2.5 mg o.d. |
| ESRD | 6.25 mg o.d. | 5 mg o.d. | 25 mg o.d. | 50 mg o.d. | Contraindicated |
| Renal dialysis | 6.25 mg o.d. | 5 mg o.d. | 25 mg o.d. | 50 mg o.d. | Contraindicated |
- Citation: Florentin M, Kostapanos MS, Papazafiropoulou AK. Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment. World J Diabetes 2022; 13(2): 85-96
- URL: https://www.wjgnet.com/1948-9358/full/v13/i2/85.htm
- DOI: https://dx.doi.org/10.4239/wjd.v13.i2.85